Disseminated Mucormycosis Due to Lichtheimia Corymbifera During Ibrutinib Treatment for Relapsed Chronic Lymphocytic Leukaemia: A Case Report

Clinical Microbiology and Infection - United Kingdom
doi 10.1016/j.cmi.2018.10.004
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Comparison of Innate Immunity Changes Following Ibrutinib and Venetoclax Treatment of Relapsed Chronic Lymphocytic Leukaemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Disseminated Mucormycosis (DM) After Pneumonectomy: A Case Report

BMC Infectious Diseases
Infectious Diseases
2016English

Unravelling the Suboptimal Response of TP53 -Mutated Chronic Lymphocytic Leukaemia to Ibrutinib

British Journal of Haematology
Hematology
2018English

Treatment Options for High-Risk Chronic Lymphocytic Leukaemia

Therapeutic Advances in Hematology
Hematology
2011English

Chronic Lymphocytic Leukaemia

Nature Reviews Disease Primers
Medicine
2017English

Gastrointestinal Bleeding Due to Large Bowel Infiltration by Chronic Lymphocytic Leukaemia.

Postgraduate Medical Journal
Medicine
1986English

Lack of Adequate Pneumococcal Vaccination Response in Chronic Lymphocytic Leukaemia Patients Receiving Ibrutinib

British Journal of Haematology
Hematology
2017English

Comparative Analysis of Targeted Novel Therapies in Relapsed, Refractory Chronic Lymphocytic Leukaemia

Haematologica
Hematology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy